Q-omics provides the consensus-scored NUAK2 profile across patient tissues and cancer cell-line models. NUAK2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NUAK2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, NUAK2 RNA expression shows 18,392 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where NUAK2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUAK2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUAK2 survival associations across molecular data types. NUAK2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUAK2 RNA expression–survival associations across cancer types. High NUAK2 expression shows unfavorable associations in UVM, UCEC and LGG, but favorable associations in PAAD, KIRC and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NUAK2 RNA expression.
This table summarizes NUAK2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NUAK2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUAK2 shows lower tumor expression in KIRC, KICH, THCA and KIRP and higher tumor expression in LIHC and BRCA. The KIRC box plot shows higher NUAK2 RNA expression in normal versus tumor tissue (log2 FC = −2.279, t-test p < 0.001).
This table shows molecular features associated with NUAK2 in patient tissues and cancer cell lines. In patient samples, NUAK2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUAK2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
